Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor gamma Activity and on Glucose Uptake by Thiazolidinediones.
10.4093/dmj.2011.35.4.340
- Author:
Kyeong Won LEE
1
;
Yun Hyi KU
;
Min KIM
;
Byung Yong AHN
;
Sung Soo CHUNG
;
Kyong Soo PARK
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. kspark@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Diabetes mellitus, type 2;
Peroxisome proliferator-activated receptors;
PPAR gamma;
Sulfonylurea compounds;
Thiazolidinediones
- MeSH:
Adipocytes;
Diabetes Mellitus, Type 2;
Glipizide;
Glucose;
Insulin;
Insulin Resistance;
Peroxisome Proliferator-Activated Receptors;
Peroxisomes;
PPAR gamma;
Receptors, Cytoplasmic and Nuclear;
Sulfonylurea Compounds;
Thiazolidinediones;
Transcriptional Activation
- From:Diabetes & Metabolism Journal
2011;35(4):340-347
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Sulfonylurea primarily stimulates insulin secretion by binding to its receptor on the pancreatic beta-cells. Recent studies have suggested that sulfonylureas induce insulin sensitivity through peroxisome proliferator-activated receptor gamma (PPARgamma), one of the nuclear receptors. In this study, we investigated the effects of sulfonylurea on PPARgamma transcriptional activity and on the glucose uptake via PPARgamma. METHODS: Transcription reporter assays using Cos7 cells were performed to determine if specific sulfonylureas stimulate PPARgamma transactivation. Glimepiride, gliquidone, and glipizide (1 to 500 microM) were used as treatment, and rosiglitazone at 1 and 10 microM was used as a control. The effects of sulfonylurea and rosiglitazone treatments on the transcriptional activity of endogenous PPARgamma were observed. In addition, 3T3-L1 adipocytes were treated with rosiglitazone (10 microM), glimepiride (100 microM) or both to verify the effect of glimepiride on rosiglitazone-induced glucose uptake. RESULTS: Sulfonylureas, including glimepiride, gliquidone and glipizide, increased PPARgamma transcriptional activity, gliquidone being the most potent PPARgamma agonist. However, no additive effects were observed in the presence of rosiglitazone. When rosiglitazone was co-treated with glimepiride, PPARgamma transcriptional activity and glucose uptake were reduced compared to those after treatment with rosiglitazone alone. This competitive effect of glimepiride was observed only at high concentrations that are not achieved with clinical doses. CONCLUSION: Sulfonylureas like glimepiride, gliquidone and glipizide increased the transcriptional activity of PPARgamma. Also, glimepiride was able to reduce the effect of rosiglitazone on PPARgamma agonistic activity and glucose uptake. However, the competitive effect does not seem to occur at clinically feasible concentrations.
